

Accuracy of ^{99m}Tc -sestamibi scintimammography for breast cancer diagnosis

SONIA MARTA MORIGUCHI¹, LAURIVAL ANTÔNIO DE LUCA^{3*},
BEATRIZ LOTUFO GRIVA², KÁTIA HIROMOTO KOGA², EDUARDO TINOIS DA SILVA¹,
HELOISA DE LUCA VESPOLI³ and GILBERTO UEMURA³

¹Department of Nuclear Medicine, Barretos Cancer Hospital, CEP 14784-400 Barretos; Departments of

²Nuclear Medicine, and ³Obstetrics and Gynecology, Botucatu Medical School, São Paulo
State University (UNESP), CEP 18618-970 Botucatu, São Paulo, Brazil

Received August 26, 2009; Accepted October 19, 2009

DOI: 10.3892/etm_00000033

Abstract. Scintimammography using ^{99m}Tc -sestamibi is a noninvasive and painless diagnostic imaging method that is used to detect breast cancer when mammography is inconclusive. Because of the advantages of labeling with ^{99m}Tc -sestamibi and its high efficiency in detecting carcinomas, it is the most widespread agent for this purpose. Its accumulation in the tumor has multifactorial causes and does not depend on the presence of architectural distortion or local or diffuse density variation in the breast. The objective of this study was to evaluate the accuracy of scintimammography for detecting breast cancer. One hundred and fifty-seven patients presenting 158 palpable and non-palpable breast nodules were evaluated. Three patients were male and 154 were female, aged between 14 and 81 years. All patients underwent scintimammography, and the nodule was subjected to cytological or histological study, i.e., the gold standard for diagnosing cancer. One hundred and eleven malignant and 47 benign nodules were detected, with predominance of ductal carcinomas (n=94) and fibroadenoma/fibrocystic condition (n=11/n=11), respectively. The mean size was 3.11 cm (7-10 cm) among the malignant nodules and 2.07 cm among the benign nodules (0.5-10 cm). The sensitivity, specificity, positive predictive value, negative predictive value and accuracy were 89, 89, 95, 78 and 89%, respectively. Analysis on the histological types showed that the technique was more effective on tumors that were more aggressive, such as ductal carcinoma. In this study, ^{99m}Tc -sestamibi scintimammography

was shown to be an important tool for diagnosing breast cancer when mammography was inconclusive.

Introduction

Mammography is the safest method for breast cancer screening (1-3). It presents good sensitivity for detecting palpable and non-palpable lesions and low specificity for distinguishing between benign and malignant processes (4). Hence, a biopsy is often required for diagnostic confirmation (5). It also presents limitations in relation to detection of lesions in dense breasts (6-8). Mann *et al* demonstrated that false negative mammograms cause delays in undertaking biopsies among patients with cancer (9).

The high rates of unnecessary biopsies in cases of benign lesions (10) have encouraged research on non-invasive techniques with greater precision. Ultrasound, magnetic resonance imaging, positron emission tomography and scintigraphy are important aids for detecting cancer when mammography is indeterminate (11). High-risk patients (e.g., family antecedents, atypical proliferative lesions and previous cancer subjected to tumorectomy or radiotherapy) have benefited from combined use of these methods (11). Scintigraphy is a noninvasive imaging examination that uses small doses of radiation (12). It is painless, its cost and availability are reasonable and it enables functional or metabolic evaluation of various organs or structures. Its advantage is unequivocal, especially when analysis using other methods is limited, and it stands out as a diagnostic evaluation method for breast cancer. Sestamibi became commercially viable at the start of the 1990s and was proposed as an alternative to thallium 201 for investigating myocardial perfusion. Because of the advantages of the physical characteristics of labeling with ^{99m}Tc , the transition from thallium 201 to ^{99m}Tc -sestamibi for applications within nuclear oncology occurred naturally (13).

The exact mechanism for the way in which ^{99m}Tc -sestamibi becomes concentrated in tumors is not completely clear, and there are probably multiple causes. It is distributed inside tissues in proportion to the blood flow and penetrates

Correspondence to: Dr Sonia Marta Moriguchi, Department of Nuclear Medicine, Barretos Cancer Hospital, Rua Antenor Duarte Villela no. 1331, CEP 14784-400 Barretos, São Paulo, Brazil
E-mail: soniamoriguchi@terra.com.br

*In memoriam

Key words: scintimammography, breast cancer, ^{99m}Tc -sestamibi

cells by passive diffusion. By means of the difference in transmembrane potential, it attaches to mitochondria, especially in malignant cells with higher negative potential (14,15). Approximately 90% of this radiopharmaceutical is concentrated in mitochondria (16). Greater accumulation in lesions depends on the mitochondrial activity and density, cellularity, angiogenesis and presence of malformed vessels (17). Cell proliferation and desmoplastic activity factors also seem to be involved (18). The presence of architectural distortion and diffuse or localized increase in breast density do not change the ^{99m}Tc -sestamibi uptake in the lesion (19-24).

Materials and methods

One hundred and fifty-seven patients of both genders who underwent scintimammography were included. These patients presented palpable and non-palpable nodules, with cytological or histological confirmation of the lesions by means of fine-needle aspiration puncture, biopsy or excision of the lesion. Patients with bilateral carcinomas, acute inflammatory or infectious processes associated with the nodule, or inadequate scintimammograms were excluded from this study.

Scintimammography. The images were acquired using a Siemens-Orbiter scintillation camera, connected to an Icon computer, with software version 7.5. A low-energy, high-resolution collimator was used, with a matrix of 128x128 pixels and 15% windows centered on a 140 keV photopeak. A magnification factor of two was used for the lateral and oblique images of the breasts, while no magnification was used for the anterior projection of the chest and axillae. Images started 10 min after injection and lasted for 10 min.

For all of the scintigraphy examinations, sestamibi (Cardiolite[®]) was used. The preparation, labeling with ^{99m}Tc and quality control followed the manufacturer's recommendations. The dose administered ranged from 370 to 740 MBq (10-20 mCi) and was injected intravenously, preferably into a vein in the foot or in the arm contralateral to the compromised breast.

The images were captured in accordance with the protocol proposed by Diggles *et al* (25) and Khalkhali *et al* (26), using a special foam mattress of 30 cm in height, with lateral openings corresponding to the projected locations of the breasts. Lateral and posterior oblique images were obtained with the patient in a prone position, with one of the breasts hanging and fitted into the opening, while maintaining the edges completely free. Filling foam was placed in the contralateral opening, so that the contralateral breast was pressed against the mattress, thereby not allowing radiation to be transmitted to the breast under examination.

Two images of each breast were obtained 10 min after administration of ^{99m}Tc -sestamibi, beginning with the lateral projection of the breast with the suspected lesion. The axillary region and muscle wall were included in the field of view, and the breast was centralized from the neck to the abdomen, following the posterior oblique ipsilateral projection at 40°. After obtaining these images, the breast positioning was changed. Then, with the patient in a supine position with raised arms, an image of the anterior thoracic region was acquired, also covering the axillary region bilaterally.

The scintimammograms were evaluated on the computer screen, with manipulation of color, brightness and intensity, and the appearance and intensity of the ^{99m}Tc -sestamibi concentration in the breast were also analyzed. The images were interpreted by two experts in nuclear medicine independently. If their diagnoses did not coincide, agreement was reached by consensus. The scintimammograms were classified respectively as positive or negative for the malignant process, according to the presence or absence of focal uptake ^{99m}Tc -sestamibi uptake, at low, medium or high intensity. Scintimammograms without focal accumulations were classified as normal when they presented diffuse and homogeneous uptake and as benign alterations when they presented diffuse and heterogeneous uptake.

Histopathological diagnosis. All of the nodules were subjected to cytological and/or histological study. Fine-needle aspiration puncture was performed using a Cameco puncture lever connected to a 10-ml syringe and 25x6-mm needle (27). The smears that were fixed in 95% alcohol were stained using the Shorr method and the smears that were air-dried were stained using the Giemsa method. Histological sections (4 μm) were obtained from specimens embedded in paraffin and were stained using H&E.

Statistical analysis. The positive and negative scintimammogram results were compared with the cytological or histological evaluation, which was considered to be the gold standard for diagnosing breast cancer. Sensitivity (S), specificity (SP), positive predictive value (PPV), negative predictive value (NPV) and accuracy were investigated, and false positive (FP) and false negative (FN) rates were established for the qualitative evaluation. These parameters were calculated in accordance with Faraj *et al* (28) as follows: $S = TP/(TP + FN)$; $SP = TN/(TN + FP)$; $PPV = TP/(TP + FP)$; $NPV = TN/(TN + FN)$; $\text{accuracy} = TP + TN/(TP + TN + FP + FN)$. The prevalence rate expressed the number of malignant tumors in the study population.

Comparisons between the means of pairs of independent data sets were carried out using the two-tailed Student's t-test, with calculation of t and p statistics (29-32).

Comparisons between pairs of independent classificatory samples were made using the Chi-square test, with calculation of χ^2 and p statistics (29-32).

Results

Among the 157 selected patients with breast nodules who underwent scintimammography, one presented two nodules in the same breast and therefore 158 nodules were detected. The majority of the patients were female (154, 98.1%), while three were male (1.9%). The age group ranged from 14 to 81 years, with a mean of 53.7 ± 14 years and median of 54 years. The mean age was significantly greater among the patients with malignant nodules (57.2 ± 11.9) than among those with benign nodules (44.4 ± 13.4); $t = 5.94$; $p < 0.001$.

In total, 111 malignant nodules and 47 benign nodules were detected, with sizes ranging from 0.5 to 10 cm ($x = 2.80 \pm 1.53$ cm). Among the malignant nodules, ductal carcinomas prevailed (Table I) and among the benign

Table I. Results of scintimammography for malignant nodules (n=111).

Malignant nodules	Scintimammography		
	Positive	Negative	Total
Ductal carcinoma	88	6	94
Ductal <i>in situ</i> carcinoma	2	1	3
Ductal-lobular carcinoma ^a	0	3	3
Lobular carcinoma	3	0	3
Mucinous carcinoma	2	1	3
Medullary carcinoma	2	0	2
OBCAM	1	0	1
Papilliferous carcinoma	1	0	1
Tubular carcinoma	0	1	1
Total	99	12	111

^aDuctal carcinoma with lobular invasion. OBCAM, occult breast carcinoma with axillary metastasis.

Table II. Results of scintimammography for benign nodules (n=47).

Benign nodules	Scintimammography		
	Positive	Negative	Total
Fibroadenoma	3	8	11
Fibrocystic condition	1	10	11
Lipoma	1	5	6
PEL without atypias	0	6	6
Negative for neoplasia	0	5	5
Interductal fibrosis	0	1	1
Adipose and fibrous tissue	0	1	1
Cystic lesion	0	1	1
Abscess	0	1	1
Adipose cells	0	1	1
Fibrolipoma	0	1	1
Intraductal papilloma	0	1	1
Chronic mastitis	0	1	1
Total	5	42	47

PEL, proliferative epithelial lesion.

nodules, fibroadenomas and fibrocystic conditions prevailed (Table II). The scintimammograms were positive for 99 malignant and 5 benign nodules. The false positive results included fibroadenomas (n=3), fibrocystic conditions (n=1) and lipoma (n=1). Malignant lesions with medium intensity of ^{99m}Tc-sestamibi occurred most frequently (64.6%), followed by high intensity (20.2%) and then low intensity (15.2%). Among the benign nodules, no high intensity was observed; 80% (n=4) were low intensity and 20% (n=1) were medium intensity.

Negative scintimammograms were observed for 54 breasts; 42 benign nodules and 12 malignant. The false negative results were observed in ductal carcinoma (n=6), *in situ* carcinoma (n=1), ductal carcinoma with lobular invasion (n=3), mucinous carcinoma (n=1) and lobular carcinoma (n=1).

The statistical analysis was carried out by comparing the positive and negative scintimammogram results for all nodules (n=157), thus resulting in S, 89%, SP, 89%, PPV, 95%, NPV, 78% and accuracy, 89%.

Discussion

Breast carcinomas are more frequent among older patients, whereas benign disease occurs more among younger groups, especially during the premenopausal phase (33). Our results are in agreement with these epidemiological data.

In our sample, the vast majority were women. Three men were evaluated, one with a malignant tumor and two with benign tumors. Case reports using ^{99m}Tc-MDP (34), ^{99m}Tc-sestamibi (35) and ^{99m}Tc-tetrofosmin (36) have shown the diagnostic usefulness of scintigraphy for detecting breast cancer. We did not find any other studies that included breast tumors among men. Our investigation seems to demonstrate that scintimammography is effective for differentiating malignant and benign tumors among men.

Among the proposed radiotracers for detecting breast tumors, ^{99m}Tc-sestamibi is the one that has been studied most (37-50). We chose this tracer since it was available on a day-to-day basis for cardiological evaluations, thus allowing a combined routine for scintimammography. The facts that its results have been more effective and that it had FDA approval (51) before other tracers were also important in this choice.

The diagnostic value of scintimammography was reevaluated in extensive meta-analyses carried out by Waxman (52), Taillefer (13) and Liberman *et al* (53). Waxman found that the sensitivity was between 84 and 94% (61). Higher results have been observed for palpable lesions (84-100%), in comparison with non-palpable lesions (25-75%). The overall specificity ranges between 72 and 94%, with values between 74 and 87% for palpable lesions and between 86 and 90% for non-palpable lesions. The prevalence of cancer ranged from 39 to 84% in the populations studied. Taillefer evaluated 2009 patients and found the means and intervals for sensitivity (85%; 67-95%), specificity (89%; 58-100%), accuracy (86%; 73-92%), PPV (89%; 67-100%) and NPV (84%; 55-97%) (13). In a recent study, Liberman *et al* found a sensitivity of 85.2% and specificity of 86.6% (53). The sensitivity was greater for palpable masses (87.8%) than for non-palpable masses (66.8%). Specificity did not vary. Our results are in agreement with the meta-analyses of Waxman (52) and Liberman *et al* (53). Hussain and Buscombe in the meta-analysis study conclude that there is evidence that scintimammography is a robust imaging technique delivering high sensitivities and specificities too (54).

In Brazil, the first experience with scintimammography using ^{99m}Tc-sestamibi was reported by Barros *et al* (55), in 1995, in an analysis of 50 patients with nodules larger than 1 cm. These authors observed sensitivity, specificity, PPV, NPV and accuracy of 96.8, 77.7, 85.5, 93.3 and 90%, respectively. They studied 32 cases of carcinoma, 10 of

fibrocystic abnormality, 6 of fibroadenoma, 1 of phyllodes tumor and 1 of papilloma. Five years later, Lima *et al* (56) studied 50 patients with palpable nodules or mammographic abnormalities and found a sensitivity of 100%, specificity of 80%, PPV of 85.3%, NPV of 100% and accuracy of 90.7%. Our sample was three times larger than these two Brazilian studies, with the additional inclusion of lesions smaller than 1 cm and different histological types of carcinomas, including those with good prognosis. Neither of the above-mentioned studies provided descriptions of the size and histological type of the carcinomas. These factors may have caused a difference in the observed sensitivity for detecting breast cancer.

Factors that cause greater tumor aggressiveness increase the ^{99m}Tc -sestamibi uptake, and it is also influenced by the histological type and grade (57,58). Tumors that are more aggressive concentrate more than those with a better prognosis. Buscombe *et al* demonstrated that ductal carcinoma causes accumulation of ^{99m}Tc -sestamibi (57). Papilliferous and mucinous carcinomas, with lesser cellularity and slow growth, frequently do not show significant concentrations of the radiotracer. Ductal carcinomas predominated in our sample (84.7%) and their prevalence was even greater than that reported by Tavassoli (47 to 75%) (59). These are aggressive tumors and their prognosis depends on the time of the diagnosis, volume, axillary involvement and histological grade (59). Occult breast carcinomas with axillary metastasis are rare, with an incidence of 0.3 to 0.8% (60-63). We found one case in our study, representing 0.9% of the patient sample.

The positive scintimammograms also showed subclavicular dissemination of occult breast carcinoma. Scoggins *et al* (64) reported the case of a patient with a palpable nodule in the right axilla, using ^{18}F -FDG. We noted the usefulness of scintimammography in this type of disease too. Among the *in situ* carcinomas, the only tumor with necrosis (which is an indicator of poor prognosis) (59) was not detected by scintimammography, possibly due to its small size and more central location. For the other two, which had greater volume, the scintimammogram was positive. Due to epithelial proliferation, fibroadenomas and fibrocystic disease can concentrate the radiotracers, thereby resulting in false positive images (20,38,39,59,68,69). We observed that three cases of fibroadenoma and one of fibrocystic condition were positive on scintimammograms. Lipoma was another benign lesion that was positive on scintimammograms, but no histological factors were correlated with this finding.

Scintimammography is a method with excellent reproducibility for detecting breast cancer. Since early diagnosis of breast cancer determines the evolution of the disease, all the lesions detected by scintimammography require microscopic study, even after taking into account the possibility of finding false positives. Considering that some researchers have correlated the presence of proliferative conditions with greater relative risk of developing breast cancer (64,65), and that *in situ* carcinomas may be associated with fibroadenomas (66), patients who undergo a scintimammography may benefit from this diagnostic approach. On the other hand, scintimammography supplies additional information for this disease, after it has been suggested by mammography. In cases of negative scintimammograms, it is highly likely that the tumors are benign.

Neoplasia with a poor prognosis is aggressive and grows rapidly (56). Such tumors present high expression of cellular proliferation factors, high mitotic rates, intense angiogenesis and high mitochondrial activity and density. These factors are the main determinants for the concentration of ^{99m}Tc -sestamibi in the lesion (13-17,54,55).

In conclusion, scintimammography showed excellent reproducibility for detecting breast carcinomas, especially ductal carcinomas. Although it is not a method indicated for screening, it allows diagnostic confirmation by means of biopsies because of its high specificity.

References

1. Sickles EA: Breast masses: mammographic evaluation. *Radiology* 173: 297-303, 1989.
2. Donegan WL: Evaluation of a palpable breast mass. *N Engl J Med* 327: 937-942, 1992.
3. Kopans DB: Rastreamento do câncer de mama. In: Kopans DB and Bertud M: *Imagem da Mama*. 2nd edition. Medsi, Rio de Janeiro, pp55-99, 2000.
4. Sickles EA: Mammographic features of 300 consecutive nonpalpable breast cancers. *Am J Roentgenol* 146: 661-663, 1986.
5. Khalkhali I, Mena I and Diggles L: Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi. *Eur J Nucl Med* 21: 357-362, 1994.
6. Kalisher L: Factors influencing false negative rates in xeromammography. *Radiology* 133: 297-301, 1979.
7. Rosenberg RD, Hunt WC, Williamson MR, *et al*: Effects of age, breast density, ethnicity and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. *Radiology* 209: 511-518, 1998.
8. Mandelson MT, Oestreicher N, Porter PL, *et al*: Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. *J Natl Cancer Inst* 92: 1081-1087, 2000.
9. Mann BD, Giuliano AE, Basset LW, Barber MS, Hallauer W and Morton DL: Delayed diagnosis of breast cancer as a result of normal mammograms. *Arch Surg* 118: 23-24, 1983.
10. Vespoli HM, De Luca LA, Rodrigues JR and Uemura G: Natureza histopatológica de microcalcificações presentes em lesões não nodulares classificadas como Birads 4. *Rev Bras Mastol* (In press).
11. Waxman AD, Ramanna L, Memsic LD, *et al*: Thallium scintigraphy in the evaluation of mass abnormalities of the breast. *J Nucl Med* 34: 18-23, 1993.
12. Lyra M and Vamvakas I: Dosimetry in scintimammography by (99m)Tc-MuIotaBetaIota, (99m)Tc-tetrofosmin, (99m)Tc-(V) DMSA and 201TlCl compared with X-rays mammography. *Hell J Nucl Med* 12: 184-188, 2009.
13. Taillefer R: The role of 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. *Semin Nucl Med* 19: 16-40, 1999.
14. Chiu ML, Kronauge JF and Piwnica-Worms D: Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblasts. *J Nucl Med* 31: 1646-1653, 1990.
15. Piwnica-Worms D, Kronauge JF and Chiu ML: Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. *Circulation* 82: 1826-1838, 1990.
16. Carvalho PA, Chiu ML, Kronauge JF, *et al*: Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. *J Nucl Med* 33: 516-522, 1992.
17. Omar WS, Eissa S, Moustafa H, Farag H, Ezzat I and Abdel-Dayem HM: Role of thallium 201 chloride and Tc99m methoxy-isobutyl-isonitrile sestamibi in evaluation of breast masses: correlation with immunohistochemical characteristic parameters Ki-63 PCNA, BCL-2 and angiogenesis in malignant lesions. *Anticancer Res* 17: 1639-1644, 1997.
18. Cutrone JA, Yosur LS, Khalkhali I, *et al*: Immunohistologic assessment of technetium-99m-MIBI uptake in benign and malignant breast lesions. *J Nucl Med* 39: 449-453, 1998.

19. Tierney S, Fenlon HM, Phelan N, O'Sullivan P, Ennis JT and Gorey TF: Scintimammography in the assessment of local recurrence following conservative breast surgery. *Br J Surg* 85: 51, 1998.
20. Cutrone JA, Khalkhali I, Yosur LS, *et al*: Tc-99m sestamibi scintimammography for the evaluation of breast masses in patients with radiographically dense breasts. *Breast* 5: 383-388, 1999.
21. Zegel H, Heller L, Edell S, Squires F and Rubin J: Tc-99m sestamibi scintimammography dense breast. *Clin Nucl Med* 24: 968-975, 1999.
22. Kuhn JC, Siegel A, Poplack S and Arrick B: Chest wall recurrence of breast cancer detected by scintimammography. *Clin Nucl Med* 25: 104-107, 2000.
23. Kolasinska AD, Cwikla JB, Buscombe JR, *et al*: Scintimammography in recurrent breast cancer: a primary or secondary role? *Nucl Med Commun* 21: 389-390, 2000.
24. Usmani S, Khan HA, Niaz K, *et al*: Tc-99m-methoxy isobutyl isonitrile scintimammography: imaging postexcision biopsy for residual and multifocal tumor. *Nucl Med Commun* 29: 826-829, 2008.
25. Diggles L, Mena I and Khalkhali I: Technical aspects of prone dependent-breast scintimammography. *J Nucl Med Technol* 22: 165-170, 1994.
26. Khalkhali I, Mena I and Jouanne E: Prone scintimammography in patients with suspicion of breast cancer. *J Am Coll Surg* 78: 491-497, 1994.
27. Zajicek J: Aspiration biopsy cytology Part I. Cytology of supra diaphragmatic organs. *Basel: S. Karger* 4: 37;38;48, 1974.
28. Faraj M, Antunes LC and Ribeiro RM: Aspectos básicos da interpretação dos exames complementares. *J Bras Med* 62: 124-129, 1992.
29. Siegel S: Estatística não Paramétrica (Para as Ciências do Comportamento). McGraw Hill, São Paulo, 1975.
30. Fleiss JL: Statistical Methods for Rates and Proportions. John Wiley, New York, 1973.
31. Rosner B: Fundamental of Biostatistics. 2nd edition. Duxbury Press, Boston, 1986.
32. Curi PR: Metodologia e Análise de Pesquisa em Ciências Biológicas. 2nd edition. Tipomic, Botucatu, 1998.
33. Harris JR, Hellman S, Henderson IC and Kinne DW: Breast Diseases. Lippincott, Philadelphia, 1987.
34. Inanir S, Kiliç AK, Özdemir E and Zorlutuna Y: Technetium-99m-methylene diphosphonate scintimammography in male breast cancer. *J Nucl Med* 39: 28-29, 1998.
35. Liu M, Husain SS, Hameer HR and Gona JM: Detection of male breast cancer with Tc-99m methoxyisobutylisonitrile. *Clin Nucl Med* 24: 882-883, 1999.
36. Marwah A, Kumar R, Bharathi D, Sharma S, Bandopadhyaya GP and Malhotra A: Tc-99m Tetrofosmin uptake in male breast cancer. *Clin Nucl Med* 26: 77-78, 2001.
37. Kao CH, Wang SJ and Liu TJ: The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. *Eur J Nucl Med* 215: 432-436, 1994.
38. Khalkhali I, Cutrone JA, Mena IG, *et al*: Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. *Radiology* 196: 421-426, 1995.
39. Palmedo H, Biersack HJ, Lastoria S, *et al*: Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentric trial. *Eur J Nucl Med* 25: 375-385, 1998.
40. Khalkhali I, Villanueva-Meyer J, Edell SL, *et al*: Diagnostic accuracy of ^{99m}Tc-sestamibi breast imaging: multicenter trial results. *J Nucl Med* 41: 1973-1979, 2000.
41. Alonso O, Massardo T, Delgado LB, *et al*: Is ^{99m}Tc-sestamibi scintimammography complementary to conventional mammography for detecting breast cancer in patients with palpable masses? *J Nucl Med* 42: 1614-1621, 2001.
42. Massardo T, Alonso O, Kabasakal L, *et al*: Diagnostic value of ^{99m}Tc-methylene diphosphonate and ^{99m}Tc-pentavalent DMSA compared with ^{99m}Tc-sestamibi for palpable breast lesions. *J Nucl Med* 43: 882-888, 2002.
43. Taillefer R, Robidoux A, Lambert R, Turpin S and Laperriere J: Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. *J Nucl Med* 36: 1758-1765, 1995.
44. Khalkhali I, Cutrone J, Mena I, *et al*: Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. *J Nucl Med* 36: 1784-1789, 1995.
45. Palmedo H, Bender H, Grünwald F, *et al*: Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. *Eur J Nucl Med* 24: 1138-1145, 1997.
46. Buscombe JR, Cwikla JB, Holloway B and Hilson AJW: Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves. *J Nucl Med* 42: 3-8, 2001.
47. Rice SJ, Khalkhali I and Diggles L: The role of radionuclide breast imaging in the evaluation of suspected breast abnormalities. *Breast Dis* 10: 177-187, 1998.
48. Cwikla JB, Buscombe JR, Kelleher SM, *et al*: Comparison of accuracy of scintimammography in the diagnosis of primary breast cancer in patients selected for surgical biopsy. *Clin Radiol* 53: 274-280, 1998.
49. Khalkhali I and Vargas H: The role of nuclear medicine in breast cancer detection: functional breast imagery. *Radiol Clin of North Am* 39: 1053-1068, 2001.
50. Koukouraki S, Koukourakis MI, Vagios E, Velidaki A, Tsiftsis D and Karkavitsas N: The role of ^{99m}Tc-sestamibi scintimammography and colour Doppler ultrasonography in the evaluation of breast lesions. *Nucl Med Commun* 22: 1243-1248, 2001.
51. Nuclear imaging test cleared by the FDA. *Women's Health Weekly*, 06/09/97-06/16/97, p3,2p.
52. Waxman A: The role of ^{99m}Tc methoxyisobutylisonitrile in imaging breast cancer. *Semin Nucl Med* 27: 40-54, 1997.
53. Liberman M, Sampalis F, Mulder DS and Sampalis JS: Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature. *Breast Cancer Res Treat* 80: 115-126, 2003.
54. Hussain R and Buscombe JR: A meta-analysis of scintimammography: an evidence based approach to its clinical utility. *Nucl Med Commun* 27: 589-599, 2004.
55. Barros AC, Marques JA, Souza AZ, *et al*: Cintilografia mamária com tecnécio-99m-sestamibi: fundamentos do método e experiência clínica inicial. *Rev Ginecol Obstet* 6: 119-123, 1995.
56. Lima MCL, Cunha DC, Etchebehere ECSC, *et al*: Mamocintilografia com sestamibi-^{99m}Tc no diagnóstico de lesões de mama. *Rev Bras Mastol* 1: 3-9, 2000.
57. Buscombe JR, Cwikla JB, Thakrar DS and Hilson A: Uptake of Tc-99m MIBI related to tumor size and type. *Anticancer Res* 17: 1693-1694, 1997.
58. Nachar O, Rousseau J, Ouellet R, *et al*: Scintimammography with 11β-methoxy-(17α,20Z)-[¹²³I]iodovinylestradiol: a complementary role to ^{99m}Tc-methoxyisobutylisonitrile in the characterization of breast tumors. *J Nucl Med* 41: 1324-1331, 2000.
59. Tavassoli FA: Pathology of the Breast. Elsevier, New York, 1992.
60. Owen HW, Dockerty MB and Gray HK: Occult carcinoma of the breast. *Surg Gynecol Obstet* 98: 302, 1954.
61. Fitts WT, Steiner GC and Enterline HT: Prognosis of occult carcinoma of the breast. *Am J Surg* 106: 460, 1963.
62. Haagensen CD (ed): The diagnosis of breast carcinoma. In: Diseases of the Breast. Saunders WB, Philadelphia, p486, 1971.
63. Baron PL, More MP and Kinne DW: Occult breast cancer presenting with axillary metastases: updated management. *Arch Surg* 125: 210, 1990.
64. Scoggins CR, Vitola JV, Sandler MP, Atkinson JB and Frexes-Steed M: Occult breast carcinoma presenting as an axillary mass. *Am Surg* 65: 1-5, 1999.
65. Prats E, Aisa F, Abós MD, *et al*: Mammography and ^{99m}Tc-MIBI scintimammography in suspected breast cancer. *J Nucl Med* 40: 296-301, 1999.
66. Uriarte I, Carril JM, Quirce R, *et al*: Optimization of X-ray mammography and technetium-99m methoxyisobutylisonitrile scintimammography in the diagnosis of non-palpable breast lesions. *Eur J Nucl Med* 25: 491-496, 1998.
67. Black MM, Barclay THC and Culter SJ: Association of atypical characteristics of benign breast lesions with subsequent risk of breast cancer. *Cancer* 29: 338-343, 1972.
68. Dupont WD and Page DL: Risk factors for breast cancer in women with proliferative breast cancer in women with proliferative breast disease. *N Eng J Med* 312: 146-151, 1985.
69. Tobias P, De Luca LA, Schmitt FCL, Frederique U Jr and Uemura G: A histological review and critical analysis of fibroadenomas. *Rev Bras Mastol* 9: 68-74, 1999.